TITLE:
GVAX Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

CONDITION:
Prostate Cancer

INTERVENTION:
Immunotherapy with allogeneic prostate vaccine

SUMMARY:

      The purpose of this study is to compare the duration of survival between GVAX immunotherapy
      for prostate cancer and chemotherapy treatment in patients with prostate cancer who no
      longer respond to hormone therapy, who have documented metastases, and who have not been
      treated with chemotherapy in the past.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the
             prostate

          -  Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy

          -  Detectable metastases

          -  Any Gleason score

          -  ECOG performance status 0-2

        Exclusion Criteria:

          -  Prior treatment with chemotherapy

          -  Prior Immunotherapy

          -  Prior treatment with gene therapy

          -  Significant cancer related pain
      
